A New Hope for Endometriosis Sufferers

Proteomics International Laboratories, an Australian biotech company, has secured a vital US patent for its innovative PromarkerEndo blood test. This groundbreaking diagnostic tool has the potential to revolutionise the way endometriosis is diagnosed in the US, a country where this painful condition affects one in nine women.

The PromarkerEndo test uses specific protein biomarkers in blood samples to diagnose endometriosis, a condition that typically takes an average of seven years to diagnose through invasive surgery. By shortening the diagnostic pathway, this test could make a significant difference in the lives of millions of women in the US.

David Morris, the managing director and chief executive officer of Proteomics, said: 'The grant of this patent by USPTO is a major achievement and an important validation of the novelty and commercial potential of PromarkerEndo.'

A Three-Year Plan

Under Morris's leadership, Proteomics has developed a three-year plan to convert its proteomics science platform into a scalable diagnostics business. By adopting a capital-light route, the company is leaning on distribution partners rather than building expensive in-house sales teams.

Morris believes this model will enable earlier market adoption, lower establishment risk, and deliver better capital efficiency. By the first half of fiscal 2027, Proteomics plans to appoint an Australian distributor and launch local controlled market releases for PromarkerEndo. By the second half, it aims to have a US distribution network established and begin reimbursement submissions in both countries.

A Portfolio of Diagnostic Tests

Proteomics has not one but four tests in its portfolio, each with the potential to make a significant impact on healthcare. PromarkerD, a blood test that predicts diabetes-related chronic kidney disease up to four years before symptoms appear, is another key product. The company estimates an initial addressable market of 390,000 annual tests in the US alone.

A Bright Future Ahead

With a refreshed board, a new CEO with commercialisation experience, and a key US patent now secured, Proteomics looks to be entering a stage where the market may start asking not just what the science can do, but what the future revenue line might look like.

Key Facts:

  • One in nine women in the US suffer from endometriosis.
  • The average time taken to diagnose endometriosis is seven years.
  • Proteomics has a three-year plan to convert its proteomics science platform into a scalable diagnostics business.
  • The company aims to appoint an Australian distributor and launch local controlled market releases for PromarkerEndo by the first half of fiscal 2027.
  • Proteomics has a portfolio of four diagnostic tests, including PromarkerD, a blood test that predicts diabetes-related chronic kidney disease up to four years before symptoms appear.

The grant of this patent by USPTO is a major achievement and an important validation of the novelty and commercial potential of PromarkerEndo.